Optimization of a Human Anti-polio Monoclonal Antibody as a Potential Therapeutic Modality
Background. Vaccines have been an essential tool in bringing the world close to polio eradication, with over 99.9 percent of the global population free of poliovirus. No antiviral drugs or monoclonal antibody products, however, are currently licensed for treatment of polio. We previously isolated a human monoclonal antibody (9H2) with potent neutralizing activity against all three poliovirus…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
